PharmaTher, Inc.
https://www.pharmather.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PharmaTher, Inc.
Deal Watch: Tourmaline Will Pursue Its Thyroid Eye Disease Ambitions Following Merger With Talaris
Plus deals involving ASLAN/Zenyaku Kogyo, AstraZeneca/Cholsegen, Astellas/Cullgen, AbCellera/Confo, Blue Water/WraSer, Solve/Cereius, Prime Medicine/Cimeio, Evox/Codiak, PharmaTher/Vitruvias and Adverum/Ray.
Deal Watch: BMS Returning IL-12 Candidate To Frequent Partner Dragonfly
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.
Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
Tech Transfer Roundup: Boehringer Teams Up With A*STAR On Targeted Oncology R&D
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Transdermal
-
Drug Delivery
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice